Amgen Warns Against Conflating Oncology And Inflammation Biosimilars
As Biosimilar Sales Track To $2bn
Amgen’s management took a deep dive into biosimilar market dynamics during the company’s third-quarter earnings call, as the California-based biotech continued to enjoy success for biosimilars in the US and Europe.
